Moderna, Inc. (MRNA) explodes 86% on melanoma data
Moderna, Inc. (MRNA) explodes after Merck collaboration data showed positive Phase 3 melanoma results for its personalized cancer vaccine. The stock surged in extended trading as investors priced in a possible new oncology growth engine, though the company remains unprofitable and valuation now looks stretched.
Moderna, Inc. (MRNA) exploded 86% in after-hours trading after Merck and Moderna reported positive Phase 3 melanoma data for their personalized cancer vaccine, intismeran autogene. The result materially de-risks Moderna’s oncology platform and could open a new long-term growth path, but investors should note the stock now trades well above prior analyst targets and the company remains unprofitable.
Moderna, Inc. (MRNA) explodes on melanoma vaccine data.
The biotechnology stock printed $117.12 in extended-hours trading, compared with the prior regular-session close of $62.96, a gain of 86.02%. The catalyst is a positive Phase 3 melanoma result with Merck for Moderna's personalized cancer vaccine, intismeran autogene, also known as mRNA-4157/V940.
Key Takeaways
MRNA traded at $117.12 after hours, up 86.02% from $62.96 and above its listed 52-week high of $85.60.
Merck and Moderna said their Phase 3 melanoma study met recurrence-free survival and distant metastasis-free survival endpoints.
Moderna remains loss-making, with latest quarterly EPS of -$1.97 and stock-data EPS of -$7.98.
The stock now sits above the recent analyst target range, making execution and valuation discipline important for investors.
What's Behind Moderna (MRNA)'s 86% After-Hours Rally
On Aug. 19, Merck and Moderna announced that the Phase 3 INTerpath-001 trial met its recurrence-free survival and distant metastasis-free survival endpoints. The study tested intismeran autogene with Merck's Keytruda in patients with completely resected stage IIB through IV melanoma.
The companies said the combination produced statistically significant and clinically meaningful improvements compared with Keytruda alone. They also described it as the first combination regimen to achieve both results in this adjuvant melanoma setting. That is a concrete late-stage validation for Moderna's oncology platform, not simply another early research update.
The next stated steps are equally important. Merck and Moderna plan to present the data at an international medical meeting and engage regulators about filing submissions for intismeran autogene with Keytruda. Positive Phase 3 data can raise the probability of a future approval and increase the value assigned to related pipeline programs.
Market psychology amplified the news. Reddit discussion described MRNA as up about 70% premarket on the melanoma result, while Moderna's seven-day news sentiment score measured 0.7799. The 30-day score was 0.7603, and the 90-day score was 0.7686. That sustained positive tone helps explain why a major clinical catalyst produced such a powerful move.
How Moderna's Earnings and mRNA Platform Shape the Investment Case
MRNA is not being repriced because of a fresh earnings beat. The latest earnings history, dated July 31, shows EPS of -$1.97 against an estimate of -$1.97. The April 30 quarter produced EPS of -$3.40 against an estimate of -$2.11. The February quarter was better, with EPS of -$2.11 versus an estimate of -$2.64.
Moderna beat EPS estimates in five of the last eight quarters, but the latest result matched expectations and the company remains unprofitable. Stock data lists EPS at -$7.98. Those figures matter because the new bullish thesis depends more on future pipeline value than on current earnings power.
The company does have a commercial base. Its respiratory portfolio includes Spikevax, mRESVIA, and the seasonal flu vaccine mFLUSIVA. The FDA approved mFLUSIVA on Aug. 5, giving Moderna another product in a market where it competes with established vaccine companies.
Moderna's competitive advantage is its integrated mRNA platform and experience commercializing vaccines at scale. However, its COVID revenue base has been shrinking. The melanoma result therefore addresses the central strategic challenge: proving that mRNA can support a broader biotechnology business beyond pandemic vaccines.
Moderna's listed market capitalization is $24.98B. With negative EPS, a conventional price-to-earnings valuation offers little help. Investors instead need to value the respiratory franchise, cash resources, pipeline milestones, and the commercial potential of an approved personalized cancer vaccine.
Recent analyst targets show how sharply the market has moved beyond older assumptions. The consensus target is $47.86, with a median of $45 and a listed range from $25 to $77. Goldman Sachs raised its target to $67 from $49 on July 21, while Piper Sandler raised its target to $77 from $69 on June 26.
The $117.12 extended-hours print exceeds the listed high target of $77. Those targets predate the Aug. 19 Phase 3 announcement, so they are outdated valuation anchors for the new oncology story. Still, the gap does not prove that the market has fully priced the clinical opportunity correctly. It shows that traders have assigned substantial value to a successful filing and commercialization path before either milestone is complete.
That distinction matters. A company can have a stronger business outlook and an overheated stock price at the same time. After an 86.02% jump, investors need to separate the value of the melanoma program from short-term momentum.
Moderna's Forward Outlook After the Melanoma Vaccine Win
The Phase 3 result changes Moderna's forward narrative in a meaningful way. The company now has clinical evidence that an individualized mRNA cancer vaccine, combined with Keytruda, improved two important outcomes in resected melanoma. That evidence strengthens the case for oncology as a second growth engine.
The announcement also defines the milestones that carry the thesis forward. Moderna and Merck plan to present the data and engage regulators about filing submissions. A filing would advance the program, but it would not equal approval or commercial revenue. Investors should therefore treat the trial result as a major de-risking event, not a finished product launch.
For existing holders, the data supports viewing MRNA as more than a declining COVID vaccine trade. For new buyers, the negative EPS figure and price above prior analyst targets argue for careful position sizing rather than an automatic chase. The strongest case rests on three linked facts: positive Phase 3 endpoints, a planned regulatory filing process, and a proven mRNA manufacturing platform.
Regular-session trading will confirm whether the extended-hours move holds. A sustained move would show that the market accepts the oncology repricing beyond the initial burst, while a sharp reversal would show that momentum moved faster than fundamental conviction.
Moderna's after-hours surge has a specific catalyst: positive Phase 3 melanoma data with Merck's Keytruda. The result expands the investment story beyond vaccines, but MRNA still carries negative EPS and now trades well above prior analyst targets. The opportunity is substantial, yet the disciplined investor will value the clinical win separately from the price momentum.
MRNA is up because Moderna and Merck reported positive Phase 3 melanoma results for intismeran autogene, their personalized cancer vaccine. The trial met key recurrence-free survival and distant metastasis-free survival endpoints, which boosted confidence in Moderna’s oncology pipeline.
+Should I buy MRNA stock now?
The data is bullish, but the stock’s 86% jump means a lot of optimism is already priced in. Investors should be cautious, since Moderna is still unprofitable and the shares now trade above prior analyst targets.
+What did Moderna announce about melanoma?
Moderna and Merck said their Phase 3 INTerpath-001 study met both recurrence-free survival and distant metastasis-free survival endpoints. The result supports the combination of intismeran autogene with Keytruda in resected melanoma.
+Does this make Moderna profitable?
No, the melanoma win does not change Moderna’s current earnings profile. It improves the long-term growth story, but the company still reports negative EPS and needs successful regulatory and commercial execution to translate the data into profits.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on MRNA?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
